Research To Practice (RTP) and USF Health are pleased to offer community- and academic-based hospitals and cancer centers throughout the United States the opportunity to participate in an interactive live educational activity focused on the management of multiple myeloma. Each session in this regional series will feature a blend of didactic presentation, discussion of steering committee members’ treatment recommendations, interactive polling of attendees using keypad devices and follow-up audience Q&A.
If you are interested in hosting a session at your institution, please email our Meeting Services Department at GRTeam@ResearchToPractice.com or call (800) 233-6153.
Schedule of Events
Events to be announced
There is no registration fee for these events. However, preregistration is advised as seating is limited.
Each 1-hour CME-certified session will include 4 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for multiple myeloma (MM). Each event will employ an identical format that will include the following elements:
- Discussion of Steering Committee Members’ Treatment Recommendations
- Review of Available Clinical Research Findings
- Integration of Interactive Audience Polling Results
MODULE 1 Clinical Decision-Making for Patients with Newly Diagnosed MM; Emerging Role of Daratumumab
MODULE 2 Expanding Considerations and Complexities in the Contemporary Management of Relapsed/Refractory MM
MODULE 3 Biologic Rationale for and Available and Emerging Data with Novel Strategies Targeting B-Cell Maturation Antigen in MM
MODULE 4 Other Novel Agents and Strategies in Late-Stage Development
Each 1-hour CME-certified session will conclude with a 5-minute Q&A segment
STEERING COMMITTEE MEMBERS
Rafael Fonseca, MD
Getz Family Professor of Cancer
Director for Innovation and Transformational Relationships
Interim Executive Director of the Mayo Clinic
Comprehensive Cancer Center
Chair, Department of Internal Medicine
Distinguished Mayo Investigator
Mayo Clinic in Arizona
Phoenix, Arizona
Shaji K Kumar, MD
Professor of Medicine
Consultant
Division of Hematology and Blood and
Marrow Transplantation
Mayo Clinic
Rochester, Minnesota
Ola Landgren, MD, PhD
Professor of Medicine
Chief, Myeloma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York
Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia
Nikhil C Munshi, MD
Professor of Medicine, Harvard Medical School
Director of Basic and Correlative Science
Associate Director, Jerome Lipper Multiple
Myeloma Center
Department of Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts
Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer
Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Nina Shah, MD
Associate Professor of Medicine
University of California, San Francisco
Division of Hematology-Oncology
San Francisco, California
Project Chair
Neil Love, MD
President
Research To Practice
Miami, Florida
Target Audience
This activity is intended for medical oncologists, hematologists and other healthcare providers involved in the treatment of multiple myeloma (MM).
Learning Objectives
- Discuss available research data informing the use of monoclonal antibody therapy directed at CD38 as a component of induction therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into the clinical management of this disease.
- Customize induction, consolidation and maintenance therapeutic approaches for active MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
- Evaluate research data supporting a role for minimal residual disease (MRD) status in predicting long-term outcomes with therapy, and use this information to determine the potential role of MRD assays in protocol and nonresearch management of MM.
- Apply published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory MM.
- Discuss available data documenting the activity of CAR T-cell therapy, bispecific T-cell engagers and antibody-drug conjugates designed to target BCMA (B-cell maturation antigen), and use this knowledge to identify patients with MM who may be appropriate for these therapeutic approaches on clinical trials.
- Assess the mechanisms of action of, available data with and ongoing clinical trials evaluating other novel, investigational approaches for MM, and consider the potential role of these therapies in clinical practice.
CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.
Accreditation Statement
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
USF Health designates each live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Policy
USF Health adheres to ACCME Standards regarding commercial support of continuing medical education. It is the policy of USF Health that the faculty and planning committee disclose real or apparent conflicts of interest relating to the topics of this educational activity, that relevant conflict(s) of interest are resolved and also that speakers will disclose any unlabeled/unapproved use of drug(s) or device(s) during their presentation. Detailed disclosure will be made in the activity syllabus.
Equal Opportunity Statement
USF is an Equal Opportunity/Affirmative Action/Equal Access Institution.
Contact Information
If you have questions regarding credit, please contact cpdsupport@usf.edu, or call 813-224-7860.
Commercial Support
These activities are supported by educational grants from Adaptive Biotechnologies, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Takeda Oncology.
|
